Fremanezumab (Ajovy) (Fremanezumab-vfrm) for Personal Injury

Drug Class: CGRP Ligand Monoclonal Antibody — Preventive (Monthly or Quarterly Injection)

Common Uses

• Preventive treatment of episodic migraine
• Preventive treatment of chronic migraine
• Post-traumatic migraine following car accidents or whiplash
• Patients preferring quarterly rather than monthly injection

How It Helps in Personal Injury Cases

Fremanezumab (Ajovy) is the only CGRP monoclonal antibody available in both monthly and quarterly dosing. The quarterly option — 675mg every three months (three injections administered together) — is strategically notable for pharmacy lien documentation: a single quarterly dispensing event covers 90 days of preventive neurological treatment. A patient on quarterly Ajovy for one year generates four high-value dispensing records per year rather than twelve.

Fremanezumab neutralizes the CGRP ligand circulating in the bloodstream, preventing it from binding to CGRP receptors on trigeminal nerve fibers and cranial vessels. Monthly or quarterly injection maintains continuous CGRP neutralization between doses. Both dosing schedules demonstrated equivalent efficacy in the HALO trials.

Fremanezumab (Ajovy) for Post-Traumatic Migraine Prevention

Fremanezumab, sold as Ajovy, is a CGRP monoclonal antibody for migraine prevention with a unique feature: it is the only injectable CGRP antibody available in both monthly and quarterly dosing.

Monthly vs. Quarterly Dosing

Both schedules deliver equivalent efficacy (HALO trials). The quarterly option provides three months of coverage from a single administration.

Mechanism

Fremanezumab targets the CGRP ligand itself, neutralizing circulating CGRP before it can bind to trigeminal CGRP receptors. Monthly or quarterly injection maintains sustained CGRP suppression between doses.

Clinical Evidence

The HALO-EM trial (episodic migraine) and HALO-CM trial (chronic migraine) demonstrated statistically significant reductions in monthly migraine days with both dosing schedules versus placebo.

Documentation Value in PI Cases

Quarterly dosing creates a particularly clean documentation profile:

• Four dispensing events per year, each representing 90 days of documented preventive neurological treatment
• Each quarterly dispensing event is a high-value lien line item
• Consistent quarterly intervals clearly document the ongoing nature of post-traumatic migraine treatment

Accessing Fremanezumab Through LienScripts

Fremanezumab (Ajovy) is brand-name only. LienScripts provides pharmacy lien coverage at $0 upfront cost for qualified personal injury patients.

Dosage Forms

• Monthly: 225mg subcutaneous injection once monthly
• Quarterly: 675mg (three 225mg injections administered together) every 3 months
• Prefilled syringe or autoinjector

Common Side Effects

• Injection site reactions (pain, redness, swelling)
• Constipation (uncommon)
• Allergic reactions (rare)

Frequently Asked Questions

What is the advantage of quarterly dosing?

Quarterly dosing allows patients to receive three months of preventive coverage from a single injection visit rather than returning monthly. This improves adherence for patients who find monthly injections burdensome. Both monthly and quarterly dosing demonstrated equivalent efficacy in clinical trials.

Is quarterly Ajovy as effective as monthly?

Yes. The HALO trials included both monthly and quarterly dosing arms and both demonstrated equivalent efficacy for migraine prevention. The quarterly dose delivers the same total drug over three months as three monthly doses.

Why would a neurologist choose Ajovy over Aimovig or Emgality?

The quarterly dosing option is the main differentiator. Neurologists may choose Ajovy for patients who prefer less frequent injections, have adherence concerns with monthly dosing, or where the quarterly schedule better fits their follow-up appointments.

Is there a generic or biosimilar for Ajovy?

No. Fremanezumab is available only as Ajovy with no biosimilar alternatives currently approved in the United States.